Allorion Therapeutics Inc. has patented phosphoramidate macrocycle compounds acting as aldo-keto reductase family 1 member C3 (AKR1C3; 17β-HSD5) inhibitors potentially useful for the treatment of cancer.
The overexpression of fibroblast growth factor receptor 2b (FGFR2b) is tied to tumor progression in several malignancies, such as cholangiocarcinoma, HER2-negative gastric cancer and breast cancer. Lunan Pharmaceutical Group Corp. has developed a novel IgG1 monoclonal antibody against FGFR2b, LNF-2102, for the potential treatment of cancer.
KRAS acts as a key molecular switch in cell signaling, activated by the guanine nucleotide exchange factor SOS1. Mutant KRAS drives many cancers, yet has been difficult to target directly. SOS/pan-KRAS modulators represent a new approach that blocks the SOS1-KRAS interaction, preventing KRAS activation and suppressing oncogenic signaling across multiple KRAS variants.
Loss of FOCAD in cells impairs normal mRNA surveillance, creating a dependency on the HBS1L/PELO complex for ribosome rescue and identifying HBS1L as a potential synthetic lethal target and therapeutic vulnerability.
At the AACR-NCI-ORTC conference, researchers from Dewpoint Therapeutics Inc. presented advances in targeting MYC condensates, revealing a potential breakthrough strategy for treating cancers driven by MYC – a well-established oncogenic driver that is frequently overexpressed or amplified across a range of human cancers.
Bowhead whales (Balaena mysticetus) live year-round in the icy or near-icy waters of the Arctic and sub-Arctic. Although they migrate with the seasonal cycles of ice formation and melting, they never reach the warmer waters visited by other large marine mammals. Their adaptation to low temperatures may have also enabled them to live longer and avoid cancer, a disease closely linked to aging.
RSS
